Silodosin for the treatment of benign prostatic hyperplasia: Pharmacology and cardiovascular tolerability

Pharmacotherapy

Volumn 30, Issue 12, 2010, Pages 1303-1312

  Lepor, Herbert ^a   Hill, Lawrence A ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Watson Pharmaceuticals Inc   (United States)

Author keywords

Benign prostatic hyperplasia; BPH; Lower urinary tract symptoms; LUTS; Safety; Selective 1A adrenoceptor antagonist; Silodosin; Tolerability

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CYTOCHROME P450 3A4; DOXAZOSIN; DRUG METABOLITE; ITRACONAZOLE; KETOCONAZOLE; KMD 3213G; KMD 3293; MOXIFLOXACIN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRAZOSIN; RECEPTOR SUBTYPE; RITONAVIR; SILDENAFIL; SILODOSIN; TADALAFIL; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

ADRENERGIC RECEPTOR BLOCKING; BINDING AFFINITY; BLOOD PRESSURE; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY MONITORING; ERECTILE DYSFUNCTION; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; LOWER URINARY TRACT SYMPTOM; MALE; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; QT PROLONGATION; RECOMMENDED DRUG DOSE; RETROGRADE EJACULATION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; TREATMENT OUTCOME; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; CARDIOVASCULAR DISEASES; DRUG EVALUATION, PRECLINICAL; HUMANS; INDOLES; MALE; PROSTATIC HYPERPLASIA; URINARY TRACT INFECTIONS;

EID: 78650196744     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.12.1303     Document Type: Review

References (47)

1. Wei JT, Calhoun EA, Jacobsen SJ. Benign prostatic hyperplasia. In: Litwin MS, Saigal CS, eds. Urologic diseases in America. Bethesda, MD: National Kidney and Urologic Diseases Information Clearinghouse (updated February 2007). NIH publication no. 07-5512:43-67. Available from http://kidney.niddk.nih.gov/ statistics/uda/. Accessed November 30, 2009.
2. Lepor H. Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol 2005;7(suppl 7):S3-11.
3. Lepor H. α-Blockers for the treatment of benign prostatic hyperplasia. Rev Urol 2007;9:181-90.
4. American Urological Association (AUA). Chapter 1. AUA guideline on the management of benign prostatic hyperplasia: diagnosis and treatment recommendations, 2003 (updated 2006). Available from http://www.auanet.org/ content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph. Accessed November 24, 2009.
5. 1-Adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008;15:193-9.
6. 1A-adrenoceptor in the human prostate. J Urol 1995;154:2096-9.
7. 1c subtype. Mol Pharmacol 1994;45:703-8.
8. 1A adrenoceptors in human prostate by tissue segment binding. J Urol 2007;177:377-81.
9. 1A-adrenoceptor gene knockout. Br J Pharmacol 2008;155:1224-34.
10. 1A- adrenoceptors. Br J Pharmacol 2008;153:1485-94.
11. 1- adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract 2007;4:368-78.
12. Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003;170:649-53.
13. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 1994;113:723-8.
14. 1-adrenergic receptors by vessel bed and age. Circulation 1999;100:2236-343.
15. 1-adrenoceptors and native tissue. Mol Pharmacol 1995;48:250-8.
16. 1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634-40.
17. Gittelman MC, Hill L, Volinn W, Hoel G. Efficacy and safety of silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH): pooled results of 2 multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 studies [abstract]. Presented at the New England section American Urological Association 77th annual meeting, Rio Grande, Puerto Rico, September 25-27, 2008. Available from http://www.neaua.org/ 2008Abstracts.cgi. Accessed November 24, 2009.
18. 1A-adrenoceptor selective for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2007;16:1955-65.
19. 1-Adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi 2006;126:209-16.
20. 1-adrenoceptor antagonist, in human prostate and vasculature. J Urol 2000;164:578-83.
21. 1A-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur J Pharmacol 1996;315:73-9.
22. 1A-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther 1999;291:81-91.
23. 1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int J Urol 2001;8:177-83.
24. 1-adrenoceptors in rat tissues in relation to the pharmacokinetics. J Pharmacol Exp Ther 1999;289:1575-83.
25. 1A-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J Pharmacol Exp Ther 2001;296:160-7.
26. Watson Laboratories, Inc. Data on file. Salt Lake City, UT; 2008.
27. Watson Pharmaceuticals, Inc. Rapaflo (silodosin) prescribing information. Morristown, NJ; 2008.
28. Shimuzu T, Miyashita I, Matsubara Y, Ikeda M, Yamaguchi M. Pharmacokinetic profile of silodosin in clinical practice. Yakugaku Zasshi 2006;126:257-63.
29. Watson Laboratories, Inc. Kissei Pharmaceutical Co. study AL-2232-G, data on file. Morristown, NJ; 2004.
30. Hill LA, Volinn W, Hoel G. Exposure of the α-blocker silodosin and its major metabolites in the plasma of healthy men [abstract]. Presented at the American Society for Clinical Pharmacology and Therapeutics annual meeting, National Harbor, MD, September 15, 2009.
31. Watson Laboratories, Inc. Kissei Pharmaceutical Co. study KMD-11005, data on file. Morristown, NJ; 2004.
32. 1A-adrenoceptor antagonist silodosin in healthy men [abstract]. Presented at the American College of Clinical Pharmacy-European Society for Clinical Pharmacy international congress on clinical pharmacy, Orlando, FL, April 24-28, 2009.
33. Hill LA, Volinn W, Hoel G. Pharmacokinetics of silodosin and its primary metabolites in subjects with moderate liver dysfunction [abstract]. Presented at the American Society for Clinical Pharmacology and Therapeutics annual meeting, National Harbor, MD, September 15, 2009.
34. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Effect of renal impairment on plasma concentrations of silodosin and its main metabolites in patients with symptoms of benign prostatic hyperplasia [abstract]. Presented at the American College of Clinical Pharmacy-European Society for Clinical Pharmacy international congress on clinical pharmacy, Orlando, FL, April 24-28, 2009.
35. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 2009;74:1318-22.
36. Roehrborn CG, Lepor H, Kaplan SA. Retrograde ejaculation induced by silodosin is the result of relaxation of smooth musculature in the male urogenital tracts and is associated with greater urodynamic and symptomatic improvements in men LUTS secondary to BPH [abstract]. J Urol 2009;181:694-5.
37. Lepor H, for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998;51:892-900.
38. Narayan P, Tewari A, for the United States 93-01 Study Group. A second phase III multicenter placebo-controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998;160:1701-6.
39. 1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-24.
40. Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62:1547-59.
41. 1A-adrenoceptor antagonist silodosin (KMD-3213), a drug for the treatment of voiding dysfunction. Arzneim-Forsch Drug Res 2006;56:682-7.
42. 1A-adrenoceptor antagonist, for the treatment of symptoms associated with benign prostatic hyperplasia [abstract]. Presented at the American College of Clinical Pharmacy-European Society for Clinical Pharmacy international congress on clinical pharmacy, Orlando, FL, April 24-28, 2009.
43. 1A-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology 2010;75:520-5.
44. sanofi-aventis. Uroxatral (alfuzosin hydrochloride) prescribing information. Bridgewater, NJ; 2009.
45. Lacerda AE, Kuryshev YA, Chen Y, et al. Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol Exp Ther 2008;324:427-33.
46. U.S. Food and Drug Administration. ICH E14: guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, October 2005. Issued by the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Approved by the International Conference on Harmonisation. Available from http://www.fda. gov/cber/gdlns/iche14qtc.pdf. Accessed July 23, 2008.
47. 1A-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study. Clin Pharmacol Ther 2010;87:609-13.